N-乙酰转移酶10在肿瘤发生发展中作用的研究进展

doi:10.16352/j.issn.1001-6325.2024.11.1589

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (11): 1589-1593.doi: 10.16352/j.issn.1001-6325.2024.11.1589

N-乙酰转移酶10在肿瘤发生发展中作用的研究进展

古仲嘉, 赖思莹, 陈敦金, 杜丽丽^*

广州医科大学附属第三医院广州妇产科研究所广东省产科重大疾病重点实验室广东省妇产疾病临床医学研究中心粤港澳母胎医学高校联合实验室, 广东广州 510000

收稿日期:2023-11-13 修回日期:2024-04-03 出版日期:2024-11-05 发布日期:2024-10-31
通讯作者: ^*lilidu8107@hotmail.com
基金资助:
国家自然科学基金(82371674)

Progress on the role of N-acetyltransferase 10 in tumor development

GU Zhongjia, LAI Siying, CHEN Dunjin, DU Lili^*

Guangzhou Institute of Obstetrics and Gynecology,Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine,the Third Affiliated Hospital of Guangzhou Medical University,Guangzhou 510000,China

Received:2023-11-13 Revised:2024-04-03 Online:2024-11-05 Published:2024-10-31
Contact: ^*lilidu8107@hotmail.com

摘要/Abstract

摘要： N-乙酰转移酶10(NAT10)是一种广泛表达于多种组织和细胞中的蛋白质,NAT10的高表达与肿瘤的侵袭、转移、耐药性密切相关。NAT10促进肿瘤发生发展的机制涉及因NAT10表达或定位的改变对细胞周期、mRNA稳定性、翻译效率以及相关通路的调控等,从而影响肿瘤的发生发展及预后。

关键词: N-乙酰转移酶10, N4-乙酰胞苷修饰, 肿瘤

Abstract: N-acetyltransferase10(NAT10) is a protein widely expressed in a variety of tissues and cells. The high expression of NAT10 is closely related to tumor invasion, metastasis and drug resistance. The mechanism of NAT10 promoting tumor genesis and development involves the regulation of cell cycle, mRNA stability, translation efficiency and related pathways due to the changes in the expression or location of NAT10, thus affecting the occurrence, development and prognosis of tumors.

Key words: N-acetyltransferase10, N4-acetylcytidine, tumor

中图分类号:

R731-31

古仲嘉, 赖思莹, 陈敦金, 杜丽丽. N-乙酰转移酶10在肿瘤发生发展中作用的研究进展[J]. 基础医学与临床, 2024, 44(11): 1589-1593.

GU Zhongjia, LAI Siying, CHEN Dunjin, DU Lili. Progress on the role of N-acetyltransferase 10 in tumor development[J]. Basic & Clinical Medicine, 2024, 44(11): 1589-1593.

参考文献

[1] Arango D, Sturgill D, Alhusaini N, et al. Acetylation of cytidine in mRNA promotes translation efficiency[J]. Cell,2018,175. doi: 10.1016/j.cell.2018.10.030.
[2] Liu HY, Liu YY, Zhang YL, et al. Poly(ADP-ribosyl)ation of acetyltransferase NAT10 by PARP1 is required for its nucleoplasmic translocation and function in response to DNA damage[J]. Cell Commun Signal,2022,20:127. doi: 10.1186/s12964-022-00932-1.
[3] Zhang X, Liu J, Yan S, et al. High expression of N-acetyltransferase 10: a novel independent prognostic marker of worse outcome in patients with hepatocellular carcinoma[J]. Int J Clin Exp Pathol,2015,8:14765-14771.
[4] Ma R, Chen J, Jiang S, et al. Up regulation of NAT10 promotes metastasis of hepatocellular carcinoma cells through epithelial-to-mesenchymal transition[J]. Am J Transl Res,2016,8:4215-4223.
[5] Pan Z, Bao Y, Hu M, et al. Role of NAT10-mediated ac4C-modified HSP90AA1 RNA acetylation in ER stress-mediated metastasis and lenvatinib resistance in hepatocellular carcinoma[J]. Cell Death Discov,2023,9:56. doi: 10.1038/s41420-023-01355-8.
[6] Zhang Y, Jing Y, Wang Y, et al. NAT10 promotes gastric cancer metastasis via N4-acetylated COL5A1[J]. Signal Transduct Target Ther,2021,6:173. doi: 10.1038/s41392-021-00489-4.
[7] Wu Y, Cao Y, Liu H, et al. Remodelin, an inhibitor of NAT10, could suppress hypoxia-induced or constitutional expression of HIFs in cells[J]. Mol Cell Biochem,2020,472:19-31. doi: 10.1007/s11010-020-03776-w.
[8] Deng M, Zhang L, Zheng W, et al. Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression[J]. J Exp Clin Cancer Res,2023,42:9. doi: 10.1186/s13046-022-02586-w.
[9] Feng Z, Li K, Qin K, et al. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA[J]. J Hematol Oncol,2022,15:112. doi: 10.1186/s13045-022-01338-9.
[10] Xu D, Huang K, Chen Y, et al. Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing[J]. Front Immunol,2023,14:1133166. doi: 10.3389/fimmu.2023.1133166.
[11] Jin C, Wang T, Zhang D, et al. Acetyltransferase NAT10 regulates the Wnt/β-catenin signaling pathway to promote colorectal cancer progression via ac4C acetylation of KIF23 mRNA[J]. J Exp Clin Cancer Res,2022,41:345. doi: 10.1186/s13046-022-02551-7.
[12] Zheng X, Wang Q, Zhou Y, et al. N-acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4-acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA[J]. Cancer Commun,2022,42:1347-1366. doi: 10.1002/cac2.12363.
[13] Zhang Y, Deng Z, Sun S, et al. NAT10 acetylates BCL-XL mRNA to promote the proliferation of multiple myeloma cells through PI3K-AKT pathway[J]. Front Oncol,2022,12:967811. doi: 10.3389/fonc.2022.967811.
[14] Wei R, Cui X, Min J, et al. NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma[J]. Acta Pharmaceutica Sinica B,2022,12:3313-3325. doi: 10.1016/j.apsb.2022.01.015.
[15] Zheng J, Tan Y, Liu X, et al. NAT10 regulates mitotic cell fate by acetylating Eg5 to control bipolar spindle assembly and chromosome segregation[J]. Cell Death Differ,2022,29:846-860. doi: 10.1038/s41418-021-00899-5.
[16] Wang G, Zhang M, Zhang Y, et al. NAT10-mediated mRNA N4-acetylcytidine modification promotes bladder cancer progression[J]. Clin Transl Med,2022,12:e738. doi: 10.1002/ctm2.738.
[17] Xie R, Cheng L, Huang M, et al. NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer[J]. Cancer Res,2023,83:1666-1683. doi: 10.1158/0008-5472.CAN-22-2233.
[18] Long Y, Ren Y, Wei Q, et al. NAT10-mediated RNA acetylation enhances HNRNPUL1 mRNA stability to contribute cervical cancer progression[J]. Int J Med Sci,2023,20:1079-1090. doi: 10.7150/ijms.83828.
[19] Chen X, Hao Y, Liu Y, et al. NAT10/ac4C/FOXP1 promotes malignant progression and facilitates immunosuppression by reprogramming glycolytic metabolism in cervical cancer[J]. Adv Sci (Weinh),2023,10:e2302705. doi: 10.1002/advs.202302705.
[20] Jin Z, Chai YD, Hu S, et al. Fatty acid metabolism and cancer[J]. Adv Exp Med Biol,2021,1280:231-241. doi: 10.1007/978-3-030-51652-9_16.
[21] Luo Y, Wang H, Liu B, et al. Fatty acid metabolism and cancer immunotherapy[J]. Curr Oncol Rep,2022,24:659-670. doi: 10.1007/s11912-022-01223-1.
[22] Dalhat MH, Mohammed MRS, Alkhatabi HA, et al. NAT10: an RNA cytidine transferase regulates fatty acid metabolism in cancer cells[J]. Clin Transl Med,2022,12:e1045. doi: 10.1002/ctm2.1045.
[23] Xiang Y, Zhou C, Zeng Y, et al. NAT10-mediated N4-acetylcytidine of RNA contributes to post-transcriptional regulation of mouse oocyte maturation in vitro[J]. Front Cell Dev Biol,2021,9:704341. doi: 10.3389/fcell.2021.704341.
[24] Lin J, Xiang Y, Huang J, et al. NAT10 maintains OGA mRNA stability through ac4C modification in regulating oocyte maturation[J]. Front Endocrinol,2022,13:907286. doi: 10.3389/fendo.2022.907286.
[25] Chen L, Wang WJ, Liu Q, et al. NAT10-mediated N4-acetylcytidine modification is required for meiosis entry and progression in male germ cells[J]. Nucleic Acids Res,2022,50:10896-10913. doi: 10.1093/nar/gkac594.

N-乙酰转移酶10在肿瘤发生发展中作用的研究进展

Progress on the role of N-acetyltransferase 10 in tumor development

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[2]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[3]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[4]	陈笑天, 陈翀, 罗云萍. MAFB对肿瘤相关巨噬细胞极化及功能的影响[J]. 基础医学与临床, 2024, 44(7): 965-973.
[5]	谭树芬, 何利平, 杨琳琳, 杨谢兰, 杨宏英, 姚明姣, 李树清. TBL与工作坊整合教学法在妇科肿瘤学临床教学中的应用[J]. 基础医学与临床, 2024, 44(7): 1054-1057.
[6]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[7]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[8]	王婷婷, 郭丹, 陆君阳, 徐徕, 董海涛, 林佃新, 肖毅. 结直肠神经内分泌肿瘤细胞突变类型分析[J]. 基础医学与临床, 2024, 44(4): 523-527.
[9]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.
[10]	吴玉红, 喻才元, 叶石才. NMES1基因在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 403-407.
[11]	南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.
[12]	陈雪, 罗添, 魏超君. 溶血磷脂酰胆碱酰基转移酶1在肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(2): 256-259.
[13]	刘柯, 戴梦华. 胰腺癌中谷氨酰胺代谢重构的研究进展[J]. 基础医学与临床, 2024, 44(11): 1613-1617.
[14]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[15]	刘林弟, 吕庆杰. GPSM2在肿瘤中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(10): 1447-1450.